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antibodiesAbstract Background: Antiendothelial cell antibodies (AECA) were studied in the pathogenesis
of emphysema in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension
(PH) in vasculitis, connective tissue disease and idiopathic pulmonary arterial hypertension.
Aim of the study: This study aimed to compare the level of AECA between COPD patients with
corpulmonale and those without corpulmonale.
Methods: The study involved 30 male COPD patients without corpulmonale (group 1), 30 male
COPD patients with corpulmonale (group 2) and 30 male healthy controls, (group 3). All subjects
underwent spirometric pulmonary functions’ testing, echocardiography and measurement of AECA
in serum.
Results: There was highly signiﬁcantly elevated AECA level in COPD patients with corpulmo-
nale compared to other groups. This was associated with highly signiﬁcant correlation of AECA
level and right ventricular systolic pressure (RVSP), FEV1% of predicted and signiﬁcant correlation
with arterial oxygen tension (PaO2) and oxygen saturation (SapO2) in the same group.
Conclusion: The signiﬁcantly higher level of AECA in COPD patients with corpulmonale
together with RVSP suggests a role for these autoantibodies in the pathogenesis of PH and corpul-
monale complicating COPD.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is a global dis-
ease caused by chronic exposure to tobacco smoke and other
airway irritants, like biofuel smoke [1].
The functional hallmark of COPD is airﬂow obstruction
that is not fully reversible and is usually progressive.
The disease usually presents with respiratory symptoms
590 S. Labib et al.especially dyspnea and the diagnosis is conﬁrmed by spi-
rometry [2].
The prevalence of pulmonary hypertension (PH) in stable
COPD varies from 20–91% depending on the deﬁnition of
pH (mPAP > 20 versus >25 mmHg), severity of COPD and
the method of measuring the pulmonary artery pressure (echo-
cardiography versus right heart catheterization) [3,4].
Corpulmonale refers to the altered structure (hypertrophy
or dilatation) and/or impaired function of the right ventricle
that results from pulmonary hypertension that is associated
with diseases of the lung, vasculature, upper air way, or chest
wall.
Right-sided heart disease due to left-sided heart disease or
congenital heart disease is not considered corpulmonale [5–7].
Pulmonary hypertension is the common link between lung
dysfunction and the heart in corpulmonale; echocardiography
can be a useful tool to estimate pulmonary artery systolic pres-
sure [8]. In addition it can be used to identify other causes of
PH such as congenital, valvular and myocardial disease. Spe-
ciﬁcally, the WHO has deﬁned pH as a systolic pressure greater
than 30 mmHg; this corresponds to a tricuspid regurgitant
velocity of 3 m/s on echocardiography [9].
Pulmonary vascular endothelial dysfunction is a major fac-
tor in the pathogenesis of pulmonary hypertension, inﬂamma-
tory and autoimmune processes may play a role in this regard,
through induction of endothelial dysfunction [10,11].
Antiendothelial cell antibodies (AECA) are a heteroge-
neous family of antibodies reacting with endothelial cell anti-
gens. These antibodies are found in various diseases and
recognize several antigen determinants. Different pathophysio-
logical effects have been observed in in vitro experiments,
which include direct or indirect cytotoxicity and endothelial
cell apoptosis. Furthermore, some AECA activate endothelial
cells, resulting in increased leucocyte adhesiveness, activation
of coagulation and vascular thrombosis. In animal models, it
has been shown that AECA could promote vascular damage
[12]. Recently, autoimmune mechanisms have been recognized
as being partly involved in the pathogenesis of COPD [13,14].
Circulating autoantibodies have been detected in patients with
COPD [15,16]. AECA are involved in COPD because of their
possible pathogenic function [17]. Neither the endothelial cell
antigens nor their precise role, in the pathogenicity of different
diseases in which AECA are found, is well characterized. Now-
adays, it is not known whether AECA are an epiphenomenon
accompanying vascular injury or whether they are pathogenic
[18].
Rationale
Antiendothelial cell antibodies were studied in the pathogene-
sis of pulmonary arterial hypertension in idiopathic pulmonary
arterial hypertension (iPAH), several vasculitides and connec-
tive tissue diseases, likewise, it may have a pathogenetic role in
PH and corpulmonale in some patients with COPD [19–21].
Aim of the study
The present study aimed to estimate the level of AECA in
patients with moderate-to-severe or very severe COPD and
to compare its level between COPD patients who developed
corpulmonale and those who did not.Subjects and methods
This case-control, cross-sectional study was conducted to
assess the level of AECA in 2 patient groups, 30 patients each,
COPD without corpulmonale (group I) or with corpulmonale
(group II) and a third group including 30 healthy control sub-
jects. All subjects were males, older than 40 years of age.
Patients were recruited from the attendants of chest outpatient
clinic in Suez Canal University hospitals, Ismailia and in Ain
Shams University hospitals, Cairo, Egypt. All COPD patients
met the global initiative for chronic obstructive pulmonary dis-
ease (GOLD) criteria for diagnosis of COPD with moderate to
severe and very severe disease.
All the study population gave informed written consent to
participate in the study. The following subjects were excluded:
those who experienced chest infection or acute exacerbation of
COPD in the preceding one month, subjects who could not
undergo echocardiography because of technical difﬁculty.
Patients who were under systemic steroid therapy as well as
patients with chest diseases other than COPD or with associ-
ated left-sided heart failure, vasculitis and collagen disease.
All subjects were subjected to the following: Frontal chest
radiograph, electrocardiogram (ECG), oxygen saturation
(SapO2) by pulse oximetry, arterial blood gas analysis (ABG,-
patients only), spirometric pulmonary function, echocardiog-
raphy and quantitative estimation of AECA in serum samples.
Echocardiography
Echo machine Vivd-5 GE was used to study all subjects.
Patients underwent a detailed ‘‘M-mode, two dimensional,
color Doppler, and CW Doppler imaging analysis performed
on resting patient’’ according to the recommendation of the
American Society of Echocardiography (2005) [22].
The following echocardiographic variables were measured:
1. Tricuspid annular plane systolic excursion: recorded by
M-mode from apical four chamber view by placing the
cursor on the RV free wall and tricuspid annular
motion during systole was measured (1.5–2 cm).
2. Right ventricular (RV) dimensions were taken at end
diastole from RV focused apical 4 chamber view dimen-
sions at basal level, mid level (at the tip of tricuspid valve
leaﬂets) and longitudinal dimensions were measured
from RV apex to the base, maximum accepted values
for normal RV dimensions for these parameters were
28, 33 and 79 mm respectively.
3. Free RV wall thickness, hypertrophy of right ventricu-
lar free wall ‘‘more than 5 mm’’ was measured by 2D in
subcostal four-chamber view at the tricuspid chordal
level at the peak of the R wave on ECG.
4. Peak tricuspid regurgitant jet velocity was measured by
using Bernouli equation to calculate RV systolic pres-
sure (RVSP) after adding right atrial pressure [15].
The pulmonary artery systolic pressure(PASP) is equal
to RVSP, provided there is no pulmonary valve out-
ﬂow tract obstruction or stenosis.
Antiendothelial cell antibody (AECA) level in serum was
measured using the enzyme linked immunosorbent assay
(ELISA) technique (AECA, MyBioSource, San Diego, USA).
Normal value of AECA in adult male was up to 53.8 ng/ml [23].
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Figure 1 Patients with COPD and corpulmonale have signiﬁ-
cantly higher values of AECA when compared to the other 2
groups.
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Figure 3 Non signiﬁcant positive correlation between AECA
level (ng/ml) and RVSP (mmHg) in COPD patients without
corpulmonale.
Evaluation of AECA in COPD, With, Without Corpulmonale 591Statistical analysis
All values will be analyzed using software statistical Package
of Social Science (SPSS 20 for Window-Evaluation version
An ANOVA test and Chi-square test were used. Correlations
between different parameters were evaluated using spearman
rank correlation coefﬁcient; p-values < 0.05 were considered
signiﬁcant. All data are expressed as the mean ± SD.
Results
This study comprised 3 groups of male subjects with matched
age group I, COPD patients without corpulmonale; group II:
COPD patients with corpulmonale and croup III healthy con-
trol subjects. All individuals were subjected to pulmonary
function testing, arterial oxygen saturation measurement0
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Figure 2 Signiﬁcant differences between COPD patients without
corpulmonale and COPD patients with corpulmonale regarding
FEV1%, PaO2 and SapO2.(SapO2), arterial oxygen tension (PaO2, patients only), echo-
cardiography, measurement of antiendothelial cell antibody
(AECA) in serum (Figs. 1–8, Tables 1–7).
Discussion
Chronic obstructive pulmonary disease (COPD) is deﬁned in
terms of airﬂow obstruction that is not fully reversible and60.00 70.00 80.00 90.00
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Figure 4 Highly signiﬁcant negative correlation between AECA
level (ng/ml) and FEV1% of predicted in COPD patients without
corpulmonale.
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Figure 5 Shows signiﬁcant negative correlation between AECA
level (ng/ml) and PaO2 (mmHg) in COPD patients without
corpulmonale. 50.00 100.00 150.00 200.00 250.00 300.00 350.00
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Figure 7 Highly signiﬁcant negative correlation between AECA
level (ng/ml) and FEV1% of predicted in COPD patients with
corpulmonale.
592 S. Labib et al.usually progressive. It results from an inﬂammatory process
affecting the airways and lung parenchyma. Studies conducted
at early disease revealed signiﬁcant vascular abnormalities
which result in PH and corpulmonale in more advanced dis-
ease [24–26]. Previous studies [17,27,28] suggested that an
autoimmune process might have a role in the pathogenesis of
emphysema and COPD. In the present study, we compared
the level of AECA measured quantitatively, between 2 groups
of COPD, patients with and without corpulmonale, and versus50.00 100.00 150.00 200.00 250.00 300.00 350.00
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Figure 6 Highly signiﬁcant positive correlation between AECA
level (ng/ml) and RVSP (mmHg) in COPD patients with
corpulmonale.a group of healthy control subjects. It was found that there
was a highly signiﬁcant difference in patient groups compared
to control subjects and this is consistent with the results of
karayama et al. who found signiﬁcantly higher prevalence50.00 100.00 150.00 200.00 250.00 300.00 350.00
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Figure 8 Signiﬁcant negative correlation between AECA level
(ng/ml) and PaO2 (mmHg) in COPD patients with corpulmonale.
Table 2 Comparison of right ventricular systolic pressure (RVSP) in the study groups.
Groups RVSP (mmHg)
Minimum Maximum Mean ±SD
COPD without corpulmonale 18.0 25.00 24.13 0.97
COPD with corpulmonale 32.0 92.00 58.37 16.78
Control 22.0 34.00 20.17 2.65
F – ANOVA test; p-value < 0.01 highly signiﬁcant.
The mean RVSP was 20.17 ± 2.65 mmHg among control group, 24.13 ± 0.97 mmHg among COPD without corpulmonale group and
58.37 ± 16.78 mmHg among COPD with corpulmonale group.
Table 3 Comparison of the antiendothelial cell antibody (AECA) level in the study groups.
Groups AECA level(ng/ml)
Minimum Maximum Mean ±SD
COPD without corpulmonale 55.40 91.20 64.24 9.62
COPD with corpulmonale 85.90 312.90 163.66 70.33
Control 18.60 50.10 33.96 8.95
F – ANOVA – test; p-value < 0.01 highly signiﬁcant.
Table 1 Comparison of some study characteristics in the study groups.
COPD without corpulmonale COPD withcorpulmonale Control F*/x2 p-Value
Mean ±SD Mean ±SD Mean ±SD
Age (years) 57.27 5.87 60.10 6.88 56.77 5.42 3.910* 0.132
Sex (male) 30/30 30/30 30/30 – –
Smoking
No 0 0.00 0 0.00 17 56.67 45.438 <0.01
Yes 22 73.33 25 83.33 13 43.33
Ex-Smoker 8 26.67 5 16.67 0 0.00
Smoking Index(Pack-year) 26.5 7.2 31.2 5.1 10.3 2.1 7.182* <0.01
F – ANOVA – test; v2 – Chi-square test; p-value > 0.05 non signiﬁcant; p-value < 0.01 highly signiﬁcant.
There is signiﬁcantly higher incidence of smoking and smoking index among COPD patients with or without corpulmonale compared to control
subjects.
Evaluation of AECA in COPD, With, Without Corpulmonale 593and levels of AECA in patients with COPD, than in a reference
population [17].
Antiendothelial cell antibodies (AECA) are auto antibodies
capable of reacting with different endothelial cell (EC) struc-
tures [19]. Recently Arends et al. [29] had reported the presence
of IgM and IgG AECA speciﬁcally targeting cell surface anti-
gens in the majority of patients with connective tissue disease
(CTD) – associated PH and in idiopathic pulmonary arterial
hypertension (iPAH). In the current study there were higher
levels of AECA in COPD patients with corpulmonale than
those without corpulmonale with highly signiﬁcant difference.
This ﬁnding is in accordance with Tamby et al. [21,30] who
demonstrated the presence of circulating auto antibodies
against ECs and ﬁbroblasts in iPAH and CTD – associated
PH patients with higher prevalence than in healthy control
subjects and in CTD-patient group without PH. Several recent
studies highlighted the role of ‘‘EC’’ dysfunction in the patho-
genesis of PH in COPD. [31–33] The signiﬁcantly higher level
of AECA in COPD patients with PH and corpulmonale indi-
cate that they might have a role in the pathogenesis of PH in
some COPD patients. Their presence could be initiated by
smoking induced inﬂammation and hypoxemia causing‘‘EC’’ dysfunction with expression of cellular components
identiﬁed as non-self (i.e. auto antigens). Previous studies
[27,28] have shown that tobacco smoking may promote
immune dysregulation through modulation of death pathways
of immune suppression cells or indirectly by exposing anatom-
ically sequestrated intracellular antigens to the immune
system.
In patients with COPD and PH neither the target autoanti-
gen(s) for AECA nor the mechanisms of induction of EC
injury have been identiﬁed yet. However, in other diseases,
especially connective tissue diseases and vasculitides, several
autoantigens for AECA [34–36] and mediators [29] had been
identiﬁed. The pathogenicity of AECA could include cytotox-
icity on ECs [37–39] induction of coagulation [40,41] and
apoptosis [42,43].
In the present study COPD patients were matched
regarding the grade of severity, and 8 patients with moder-
ate to severe COPD, were found to have corpulmonale. This
ﬁnding is consistent with several studies which revealed that
some patients with moderate to severe disease (FEV1
 50%) of predicted can develop PH and corpulmonale
[44–46].
Table 4 Comparison of some spirometric and oxygenation indices in the study groups.
Parameters Groups Multiple Comparison
COPD without corpulmonale COPD with corpulmonale Control
Mean ±SD Mean ±SD Mean ±SD I vs. II I vs. III II vs. III
FVC in liters 3.33 0.43 2.98 0.42 3.95 0.24 0.033 0.226 <0.01
FVC% of predicted 78.56 7.03 69.40 7.04 88.41 5.51 0.032 0.278 <0.01
FEV1 in liters 2.01 0.39 1.62 0.56 3.22 0.25 0.043 <0.01 <0.01
FEV1% of predicted 55.63 10.01 46.09 13.98 89.05 6.98 0.022 <0.01 <0.01
FEV1/ FVC% 60.70 5.24 59.11 13.03 81.49 5.70 0.521 <0.01 <0.01
MMEF (%) of predicted 57.87 13.00 48.00 11.07 0.71 0.09 0.034 <0.01 <0.01
SapO2% 88.63 2.33 82.33 6.94 96.93 1.26 0.026 <0.01 <0.01
PaO2 (mmHg) 62.77 6.13 55.40 6.66 – – 0.037 – –
F – ANOVA – test; p-value > 0.05 non signiﬁcant; p-value < 0.05 signiﬁcant; p-value < 0.01 highly signiﬁcant.
FVC: forced vital capacity; FEV1: forced expiratory volume in ﬁrst second; MMEF: Maximum Mid expiratory ﬂow; SapO2: Arterial oxygen
saturation; PaO2: Arterial oxygen tension.
Table 5 Grading of severity of COPD in patients groups.
FEV1 (%) Groups Total
COPD without corpulmonale COPD with corpulmonale
No. % No. % No. %
Mild 0 0.00 0 0.00 0 0.00
Moderate 12 40.00 8 26.67 20 33.33
Severe 12 40.00 12 40.00 24 40.00
Very Severe 6 20.00 10 33.33 16 26.67
Total 30 100.00 30 100.00 60 100.00
Chi-square 1.800
p-Value 0.406
p-Value > 0.05 non signiﬁcant.
There is higher incidence of moderate COPD among patients without corpulmonale while there is higher incidence of very severe COPD among
patients with corpulmonale; the incidence of severe COPD was equal between both groups.
Table 6 Correlation between AECA level and age, RVSP and
spirometric and oxygenation indices in COPD patients without
corpulmonale.
Parameters AECA level
r p-Value
Age (years) 0.275 0.486
RVSP (mmHg) 0.355 0.144
FVC in liters 0.604 <0.01
FVC% of predicted 0.372 0.043
FEV1 in liters 0.649 <0.01
FEV1% of predicted 0.526 <0.01
MMEF (%) of predicted 0.231 0.219
SapO2% 0.428 0.037
PaO2 (mmHg) 0.362 0.044
r – Pearson correlation coefﬁcient.
p-Value > 0.05 non signiﬁcant; p-value < 0.05 signiﬁcant; p-
value < 0.01 highly signiﬁcant.
Table 7 Correlation between AECA level and age, RVSP and
spirometric and oxygenation indices in COPD patients with
corpulmonale.
Parameters AECA level
r p-Value
Age (years) 0.207 0.137
RVSP (mmHg) 0.432 <0.01
FVC in liters 0.403 0.047
FVC% of predicted 0.356 0.035
FEV1 in liters 0.424 <0.01
FEV1% of predicted 0.473 <0.01
MMEF (%) of predicted 0.357 0.045
SapO2% 0.402 0.039
PaO2 (mmHg) 0.326 0.048
r – Pearson correlation coefﬁcient.
p-Value > 0.05 non signiﬁcant; p-value < 0.05 signiﬁcant; p-
value < 0.01 highly signiﬁcant.
594 S. Labib et al.We found also that there was signiﬁcant negative correla-
tion of AECA level with FEV1, PaO2 and SapO2 in patient
groups but not in controls, a ﬁnding consistent with other
studies [17,47]. The present study disclosed that AECA level
was elevated in COPD patients but not in the control subjects,even who smoke with positive correlation with the smoking
index. These ﬁndings are in agreement with others [27–28]
who suggested that some constituents of cigarette smoke are
potentially immunogenic capable of inducing auto antigens
in the lungs of some smokers.
Evaluation of AECA in COPD, With, Without Corpulmonale 595To our knowledge this is the ﬁrst study to evaluate the level
of AECA quantitatively in COPD patients who develop PH
and corpulmonale. Future studies on larger population sam-
ples are needed to support our ﬁndings and to conﬁrm the role
of AECA in the pathogenesis of PH in COPD, if any, so that
novel therapeutic interventions manipulating these autoanti-
bodies might help to prevent or to stop progression of pulmon-
ary hypertension complicating COPD.
In summary we found that the AECA level was signiﬁcantly
higher in COPD patients with corpulmonale compared to
patients without corpulmonale, with positive correlation with
the level of pulmonary artery systolic pressure, suggesting a
role for AECA in the pathogenesis of PH and development
of corpulmonale in these patients.
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